Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (State or Other Jurisdiction of (I.R.S. Employ ...

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2021 Earnings Conference Call August 4, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Senior Vice President, Product Development Conference Call Participants Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer & Company Joseph Thome - Cowen & ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to Commission file number 0-26301 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.01 ...

Financial Data and Key Metrics Changes - The company aims to increase the number of patients treated from over 8,000 to over 25,000 by 2025, a goal referred to as "25/25" [8][25] - The company expects to achieve approximately half of the required growth from WHO Group 1 pulmonary arterial hypertension and the other half from WHO Group 3 pulmonary hypertension [10][15] Business Line Data and Key Metrics Changes - The company anticipates gaining about 3,000 new patients each from Remodulin, Tyvaso, and Orenitram in the WHO Group 1 category [11][12][13] - The company is the only drug approved for the IPF market segment of patients with pulmonary hypertension, targeting to capture at least 9,000 patients from this group by 2025 [17] Market Data and Key Metrics Changes - There are approximately 50,000 patients being treated for pulmonary hypertension in the U.S., with about 45,000 treated with non-United Therapeutics drugs, indicating a significant market opportunity [14] - The company is focusing on educating new treaters and engaging patients to increase treatment uptake for Tyvaso in the ILD-PH segment [36] Company Strategy and Development Direction - The company is focused on expanding its patient base significantly by leveraging new product approvals and enhancing treatment options [25] - The company has several late-phase clinical trials underway, including studies for Tyvaso in COPD-associated pulmonary hypertension and ralinepag in Group 1 pulmonary hypertension [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the pulmonary hypertension market, citing a meaningful unmet need and the company's capabilities to address it [25][62] - The management believes that the goal of treating 25,000 patients by 2025 is realistic given the annual progression rates of existing patients [62] Other Important Information - The company is developing a once-daily formulation of Orenitram and less painful forms of Remodulin, expected to launch by 2025 [24] - The company is actively building relationships with new treaters and educating them about the benefits of Tyvaso [35] Q&A Session Summary Question: Strategy for Group 3 PH-ILD and patient targeting - Management indicated that they are building relationships with ILD treaters and have ongoing patient engagement efforts to educate patients about Tyvaso [30][36] Question: Commercialization plans for Tyvaso solution vs. Tyvaso DPI - Management stated that they expect a significant number of patients to transition to the dry powder inhaler, estimating a 70-30 split between dry powder and nebulizer usage [41] Question: Growth trajectory of Orenitram post-FREEDOM-EV study - Management noted that they are seeing an uptick in referrals and starts for Orenitram, with ongoing efforts to educate physicians on its value proposition [46][50] Question: TETON program and potential for DPI studies - Management confirmed that once approvals are received for Tyvaso, additional indications for DPI will follow, and they are studying patient preferences for delivery methods [57]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2020 Earnings Conference Call February 24, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairman and CEO Michael Benkowitz - President and COO Leigh Peterson - VP, Product Development James Edgemond - CFO and Treasurer Conference Call Participants Joseph Thome - Cowen and Company Liana Moussatos - Wedbush Eun Yang - Jefferies Jessica Fye - JPMorgan Martin Auster - Credit Suisse Hartaj Singh - Oppenheimer Terence Flynn - G ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (S ...

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2020 Earnings Conference Call October 28, 2020 9:00 AM ET Corporate Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairman & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Vice President, Product Development James Edgemond - Chief Financial Officer & Treasurer Conference Call Participants Hartaj Singh - Oppenheimer Eun Yang - Jefferies Martin Auster - Credit Suisse Joseph Thome - C ...

Part I. FINANCIAL INFORMATION [Consolidated Financial Statements](index=3&type=section&id=Item%201.%20Consolidated%20Financial%20Statements) This section presents the unaudited consolidated financial statements for the periods ended September 30, 2020, providing a comprehensive overview of the company's financial position, performance, and cash flows [Consolidated Balance Sheets](index=3&type=section&id=Consolidated%20Balance%20Sheets) The Consolidated Balance Sheets present the company's financial position as of September 30, 2020, highlighting changes in assets, liabilities, and equity compared to December 31, 2019 Consolidated Balance Sheet Highlights (in millions) | Metric | Sep 30, 2020 (Unaudited) | Dec 31, 2019 | | :--- | :--- | :--- | | **Total Current Assets** | $1,868.2 | $1,864.5 | | **Total Assets** | $4,411.2 | $3,913.4 | | **Total Current Liabilities** | $258.9 | $463.0 | | **Total Liabilities** | $1,128.1 | $1,133.0 | | **Total Stockholders' Equity** | $3,283.1 | $2,780.4 | [Consolidated Statements of Operations](index=4&type=section&id=Consolidated%20Statements%20of%20Operations) The Consolidated Statements of Operations detail revenues, expenses, and profitability, showing a significant turnaround in net income for the nine months ended September 30, 2020 Statement of Operations Summary (in millions, except per share data) | Metric | Q3 2020 | Q3 2019 | Nine Months 2020 | Nine Months 2019 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenues** | $380.1 | $401.5 | $1,098.4 | $1,137.7 | | **Operating Income (Loss)** | $221.1 | $183.4 | $528.3 | $(251.1) | | **Net Income (Loss)** | $171.2 | $132.4 | $416.0 | $(157.1) | | **Diluted EPS** | $3.84 | $3.01 | $9.37 | $(3.59) | [Consolidated Statements of Comprehensive Income](index=5&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Income) This statement reports changes in equity from non-owner sources, indicating a substantial improvement in comprehensive income for the nine-month period ended September 30, 2020 Comprehensive Income (Loss) (in millions) | Period | 2020 | 2019 | | :--- | :--- | :--- | | **Three Months Ended Sep 30** | $168.8 | $133.3 | | **Nine Months Ended Sep 30** | $425.7 | $(153.3) | [Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Consolidated%20Statements%20of%20Stockholders%20Equity) These statements detail changes in the company's equity accounts, primarily driven by net income and share-based compensation for the nine months ended September 30, 2020 - Total stockholders' equity increased by **$502.7 million** during the first nine months of 2020, from **$2,780.4 million** to **$3,283.1 million**[15](index=15&type=chunk) - The increase was primarily driven by a net income of **$416.0 million** for the nine-month period[15](index=15&type=chunk) [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) This statement shows the sources and uses of cash, with net cash provided by operating activities significantly improving due to the absence of a large prior-year payment Cash Flow Summary (Nine Months Ended Sep 30, in millions) | Cash Flow Activity | 2020 | 2019 | | :--- | :--- | :--- | | **Net Cash from Operating Activities** | $629.5 | $(309.1) | | **Net Cash used in Investing Activities** | $(674.7) | $(401.6) | | **Net Cash (used in) from Financing Activities** | $(23.0) | $761.2 | | **Net (Decrease) Increase in Cash** | $(68.2) | $50.5 | | **Cash and Cash Equivalents, End of Period** | $670.2 | $719.7 | [Notes to Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes provide detailed explanations of the company's accounting policies and specific financial statement items, covering business operations, investments, debt, and legal proceedings - The company's main commercial products are Remodulin, Tyvaso, Orenitram, Unituxin, and Adcirca[22](index=22&type=chunk) - As of September 30, 2020, the company had an outstanding principal balance of **$800.0 million** under its unsecured revolving credit facility, all classified as non-current[47](index=47&type=chunk) - The company is involved in significant litigation, including an antitrust lawsuit with Sandoz regarding Remodulin and patent infringement litigation with Liquidia Technologies over its NDA for LIQ861, a potential competitor to Tyvaso[76](index=76&type=chunk)[80](index=80&type=chunk)[83](index=83&type=chunk) - In the first quarter of 2019, the company expensed an **$800.0 million** upfront payment to Arena Pharmaceuticals for an exclusive license to ralinepag[88](index=88&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial condition and operational results, covering the impact of COVID-19, product performance, R&D pipeline, and liquidity [Impact of COVID-19 and Competition](index=25&type=section&id=Impact%20of%20COVID-19%20and%20Competition) Management discusses the ongoing business impact of the COVID-19 pandemic and significant competitive pressures from generic products, including those affecting Adcirca and Remodulin - The company is closely monitoring the impact of the COVID-19 pandemic, which creates considerable uncertainty for near-term revenue and product development[94](index=94&type=chunk) - Generic competition for Adcirca has had a material adverse impact on its net product sales, and the company expects increased returns of expired product beginning in 2021[101](index=101&type=chunk) - Generic versions of Remodulin have been launched in the U.S. and Europe, with European revenues coming under increasing pressure[98](index=98&type=chunk)[99](index=99&type=chunk) - The company is in patent litigation with Liquidia over its LIQ861 product, which has triggered a 30-month stay on FDA approval for LIQ861[101](index=101&type=chunk) [Research and Development](index=29&type=section&id=Research%20and%20Development) The R&D section details a robust pipeline with near-term and medium-term programs, alongside a long-term focus on organ manufacturing technologies - The Phase 3 INCREASE study of Tyvaso for PH-ILD met its primary endpoint, and an sNDA was submitted to the FDA in June 2020, with a potential decision in April 2021[126](index=126&type=chunk)[127](index=127&type=chunk) - The launch of the Remunity Pump has been delayed due to COVID-19 related supply chain issues impacting partner DEKA[119](index=119&type=chunk) - The FDA issued a Complete Response Letter (CRL) for the Trevyent NDA in April 2020; the company plans to resubmit the NDA in 2021[124](index=124&type=chunk) - Long-term R&D is focused on organ manufacturing, with a goal to commence human clinical trials of xenotransplanted kidneys in the near term[139](index=139&type=chunk) [Results of Operations Analysis](index=36&type=section&id=Results%20of%20Operations%20Analysis) This sub-section provides a detailed analysis of financial performance, highlighting revenue declines due to generic competition and significant impacts on operating expenses from share-based compensation and a one-time R&D expense Revenues by Product (in millions) | Product | Q3 2020 | Q3 2019 | % Change | | :--- | :--- | :--- | :--- | | Remodulin | $124.5 | $168.3 | (26)% | | Tyvaso | $129.5 | $110.8 | 17% | | Orenitram | $74.7 | $62.0 | 20% | | Unituxin | $37.6 | $30.1 | 25% | | Adcirca | $13.8 | $30.3 | (54)% | | **Total Revenues** | **$380.1** | **$401.5** | **(5)%** | - The decrease in nine-month R&D expense from **$1,069.0 million** in 2019 to **$231.6 million** in 2020 was primarily due to a one-time **$800.0 million** upfront payment to Arena in 2019[153](index=153&type=chunk)[155](index=155&type=chunk) - Share-based compensation (benefit) expense showed significant volatility, recording a **$(12.5) million** benefit in Q3 2020 versus a **$23.9 million** expense in Q3 2019, mainly due to stock price changes affecting the STAP liability[158](index=158&type=chunk)[160](index=160&type=chunk) [Financial Condition, Liquidity, and Capital Resources](index=41&type=section&id=Financial%20Condition%2C%20Liquidity%2C%20and%20Capital%20Resources) The company believes its liquidity, supported by substantial cash and marketable investments, is sufficient to fund operations and future plans, with strong net cash from operations Liquidity Position (in millions) | Metric | Sep 30, 2020 | Dec 31, 2019 | | :--- | :--- | :--- | | Cash and cash equivalents | $670.2 | $738.4 | | Marketable investments | $2,137.8 | $1,515.0 | | **Total** | **$2,808.0** | **$2,253.4** | - Net cash provided by operating activities for the nine months ended Sep 30, 2020, was **$629.5 million**, compared to net cash used of **$(309.1) million** in the same period of 2019[168](index=168&type=chunk)[170](index=170&type=chunk) - The company has an outstanding balance of **$800.0 million** under its credit facility, which matures in 2024[165](index=165&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section states that the company's exposure to market risk, including investment portfolio and interest rate fluctuations, has not materially changed since December 31, 2019 - The company's exposure to market risk has not materially changed since December 31, 2019[175](index=175&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) The company's disclosure controls and procedures were effective as of September 30, 2020, with no material changes to internal control over financial reporting during the quarter - The Principal Executive Officer and Principal Financial Officer concluded that disclosure controls and procedures were effective as of September 30, 2020[176](index=176&type=chunk) - No material changes to internal control over financial reporting occurred during the quarter[176](index=176&type=chunk) Part II. OTHER INFORMATION [Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 12 for information on significant legal proceedings, including antitrust litigation and patent infringement lawsuits related to key products - The company is engaged in antitrust litigation with Sandoz Inc. regarding alleged anticompetitive conduct related to the launch of a generic version of Remodulin[76](index=76&type=chunk)[77](index=77&type=chunk) - The company has filed a lawsuit against Liquidia Technologies for infringement of three patents related to Tyvaso, following Liquidia's submission of an NDA for its dry powder treprostinil product, LIQ861[83](index=83&type=chunk)[84](index=84&type=chunk) [Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) This section provides a comprehensive overview of significant risks that could adversely affect the company's business, categorized by product, legal compliance, intellectual property, and financial capacity [Risks Related to Our Products](index=44&type=section&id=Risks%20Related%20to%20Our%20Products) This subsection details risks inherent to the company's product portfolio, including reliance on key products, intense competition, clinical trial failures, manufacturing complexities, and COVID-19 disruptions - The company relies heavily on sales of Remodulin, Tyvaso, and Orenitram, and any substantial decrease in sales could materially impact operations[179](index=179&type=chunk) - The COVID-19 pandemic poses significant risks, including potential disruption of operations, delays in the development pipeline, and a decrease in revenues from existing products[189](index=189&type=chunk)[190](index=190&type=chunk)[191](index=191&type=chunk) - The company's manufacturing strategy, which involves both in-house production and reliance on third-party sole manufacturers, exposes it to significant risks of supply interruption[186](index=186&type=chunk) [Risks Related to Legal Compliance](index=51&type=section&id=Risks%20Related%20to%20Legal%20Compliance) This subsection outlines risks associated with the complex legal and regulatory landscape, including compliance with drug approval and marketing laws, anti-kickback statutes, and healthcare reform pricing pressures - The business is subject to extensive laws and regulations in the U.S. and other countries, and failure to comply could prevent or delay product commercialization[209](index=209&type=chunk) - Marketing practices are restricted by laws such as the Federal Anti-Kickback Statute and the Federal False Claims Act, with violations carrying severe penalties[211](index=211&type=chunk)[212](index=212&type=chunk) - Government healthcare reform, particularly efforts to control drug pricing, could adversely affect revenue and results of operations[215](index=215&type=chunk)[217](index=217&type=chunk) [Risks Related to Our Intellectual Property and Data Privacy](index=53&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property%20and%20Data%20Privacy) This subsection discusses intellectual property and data security risks, including potential loss of license rights, patent challenges, infringement risks, and information technology breaches - The company's patents may not effectively deter competitors, and upon expiration, could lead to generic competition and revenue loss. Patents are currently being challenged by third parties like Liquidia[230](index=230&type=chunk)[232](index=232&type=chunk) - The company is dependent on information technology systems and is vulnerable to security breaches that could compromise confidential information and lead to legal liability[237](index=237&type=chunk) - The business depends on intellectual property licensed from third parties, and termination of these agreements could result in the loss of rights to key products[227](index=227&type=chunk) [Risks Related to Our Financing Capacity, Indebtedness, and Investments](index=57&type=section&id=Risks%20Related%20to%20Our%20Financing%20Capacity%2C%20Indebtedness%2C%20and%20Investments) This subsection covers financial risks, including the potential need for additional financing, ability to service debt, and market risks associated with its investment portfolio - The company may not be able to generate sufficient cash to service or repay its **$800.0 million** in debt, which could adversely affect its financial position[240](index=240&type=chunk) - The company's investment portfolio of corporate debt and equity securities is subject to market, interest, and credit risks that may reduce its value and impact earnings[243](index=243&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=60&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no sales of unregistered equity securities or repurchases of outstanding equity securities during the nine months ended September 30, 2020 - During the nine months ended September 30, 2020, the company did not repurchase any of its equity securities or sell any unregistered equity securities[251](index=251&type=chunk) [Exhibits](index=61&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including corporate documents, officer certifications, and financial statements in iXBRL format - The exhibits filed with the report include CEO and CFO certifications pursuant to Sarbanes-Oxley Act rules[253](index=253&type=chunk) - Financial statements and notes are provided in iXBRL format as part of the exhibits[253](index=253&type=chunk)

Business Overview - United Therapeutics focuses on developing novel, life-extending technologies for patients in oncology, lung disease, and organ manufacturing[8] - The company has multiple approved therapies and over 20 years of experience addressing unmet medical needs in pulmonary arterial hypertension (PAH) and neuroblastoma (NB)[9] - United Therapeutics aims to find a cure through balance and value creation[11] Financial Performance & Product Strategy - Treprostinil revenue remains stable despite generic competition[13] - United Therapeutics believes Remodulin revenues will continue to grow due to safety, supply chain reliability, patient support, a highly differentiated product platform, and limited switching in the PAH space[17, 18, 19] - The company aims to expand its reach to 25,000 patients on PH therapies, a 3x increase from the current 7,500 patients[31, 32] Pipeline Development - Key benefits of expanded Orenitram label include a 61% reduction in risk of disease progression, improvement in key prognostic measures, a 37% reduction in risk of death, and reduced PAH-associated healthcare costs relative to selexipag[36] - Tyvaso increased the six-minute-walk-distance (6MWD) by 21 meters versus placebo (p=00043) after 16 weeks of treatment in PH WHO Group 3 patients[43] - The company is developing a pump for every PAH patient, including an implantable system for Remodulin (ISR) and Remunity[48, 49] Organ Manufacturing - United Therapeutics aims to transform the marketplace to make more organs available for transplant through EVLP, XENO, Lung Lobes, and 3DAP technologies[61] - In organ manufacturing, 152 EVLP patients' lives have been saved, Xeno kidneys have supported life for >6 months in preclinical models, Lung Lobes have achieved 70% recellularization and 15% lung function, and 60% of lungs have been 3DAP printed[64]